WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis
How to Cite
OrthoEvidence. WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis. ACE Report. 2016;5(5):7. Available from: https://myorthoevidene.com/AceReport/Report/8928
Effects of abaloparatide on vertebral, nonvertebral, major osteoporotic and clinical fracture incidence in postmenopausal women with osteoporosis: result of the phase 3 ACTIVE trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
2463 postmenopausal women with osteoporosis were randomized to one of three groups: daily subcutaneous abaloparatide (80ug), daily subcutaneous teriparatide (20ug), or daily subcutaneous placebo. The treatment period was 18 months, and patients were assessed for bone mineral density and incident fracture rate. Abaloparatide treatment was reported to result in a significantly greater increase in bo...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE